<DOC>
	<DOCNO>NCT00935467</DOCNO>
	<brief_summary>To characterize steady-state pharmacokinetics ( PK ) 2.5 mg saxagliptin administer twice daily meal healthy subject</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Study Saxagliptin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Men woman age 18 45 inclusive Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Body Mass Index ( BMI ) 18 32 kg/m² , inclusive . BMI = weight ( kg ) / [ height ( ) ] ² WOCBP unwilling unable use acceptable barrier method ( condom spermicide ) avoid pregnancy entire study period 8 week last dose investigational product Any significant acute chronic medical illness Current recent ( within 3 month ) gastrointestinal disease Any major surgery within 4 week study drug administration History allergy DPP4 inhibitor relate compound Prior exposure saxagliptin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>